Exemestane

A steroidal aromatase inhibitor (it permanently disables the enzyme molecules it binds) used in breast cancer; it also circulates in AAS contexts.

Exemestane differs from anastrozole and letrozole in a way that matters: it is a steroidal aromatase inhibitor that binds the enzyme IRREVERSIBLY, inactivating each aromatase molecule it meets. Recovery therefore depends on the body synthesising new enzyme rather than on the drug clearing, so its effect can outlast the drug's presence in plasma — the label reports suppression persisting four to five days after a single administration. Whether that makes a low-oestrogen state harder to reverse than with the reversible inhibitors has never been compared in men or steroid users. Being steroidal it has slight androgen-receptor affinity and one metabolite may have androgenic activity; whether that produces any clinical benefit or harm at labelled use is unestablished.

Oncology evidence is solid. Claims of a gentler profile than other aromatase inhibitors, or of no estrogen rebound on stopping, are sometimes made on mechanistic grounds but are not established in non-medical use.

• STRONG for its approved oncology indication in postmenopausal breast cancer, on large randomised trials.
• NONE SHOWN for use alongside testosterone or anabolic steroids — no controlled trial exists and the practice is entirely community-derived.
• STRONG in the indicated oncology population for bone-density loss and joint pain, which come from randomised data and the label. The pivotal trial also reported a higher incidence of cardiac ischaemic events than tamoxifen. The male "oestrogen crash syndrome" people describe is not an established diagnosis and has not been demonstrated as a syndrome.
• The claim that it improves lipids where non-steroidal inhibitors worsen them comes from oncology comparisons in postmenopausal women and does not establish anything about men.

Oral and irreversible — this is the pharmacological fact that distinguishes it. Because inactivated enzyme must be replaced by new synthesis, its pharmacologic effect can outlast its plasma presence. Its slight androgen-receptor affinity is a structural difference from the non-steroidal agents whose clinical significance is unestablished.

Same overshoot syndrome as every aromatase inhibitor (suppressed estrogen: libido, joints, mood, lipids, bone). An androgenic metabolite has been described, with uncertain clinical significance. Chronic low estrogen in men is a documented path to osteoporosis regardless of which molecule caused it.

• Anyone pregnant, and anyone with a hypersensitivity to it — hypersensitivity is its only labelled contraindication
• Anyone with osteoporosis or bone-density risk factors needs baseline assessment and monitoring, which is a clinician's call rather than an automatic bar
• Premenopausal women outside supervised treatment
• Anyone using it alongside steroids without a clinician

• Pregnancy — the label requires pregnancy testing, contraception during treatment and for one month after, and no breastfeeding during treatment or for one month after.
• Systemic oestrogen-containing agents, which the label says to avoid because they would oppose it.
• Strong CYP3A4 inducers, which reduce its levels.
• Other oestrogen-lowering agents, which stack toward a crash that is harder to reverse than with the reversible inhibitors.
• Any use alongside anabolic steroids is unapproved and inadequately studied.

• A prescription oncology drug; use outside that context needs a clinician, not a self-managed lab panel. Under supervision: oestradiol, with the caveat that male concentrations are hard to measure reliably.
• The label calls for baseline bone-density assessment in anyone with osteoporosis or risk factors, and routine vitamin D assessment before treatment.
• Joint pain and stiffness, which are common.
• Post-marketing reports on the label include hepatitis, hypersensitivity reactions, and tendon rupture or tendinitis.
• Mood, libido and sleep for signs of oestrogen driven too low — and here recovery is slower because the enzyme has to be rebuilt.

Unlike the reversible inhibitors, stopping does not immediately restore aromatase activity — the body has to synthesise new enzyme, and the label reports suppression persisting four to five days after a single administration. On bone and lipids: randomised follow-up found changes after two years of treatment were largely reversible a year after stopping, so "it never returns" overstates it, though recovery is variable and may be incomplete. Anyone prescribed it for cancer must not stop without their oncology team.

US: prescription-only. Products outside licensed dispensing are unapproved.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Efficacy and safety of entinostat plus exemestane in hormone receptor-positive breast cancer: a systematic review meta-analysis of randomized controlled trials
  Breast Cancer Res Treat, 2025
• The effect of exemestane administration on the lipid profile in women: Meta-analysis of randomized controlled trials
  Eur J Obstet Gynecol Reprod Biol, 2024
• Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence
  Adv Ther, 2022

• Exemestane2012
• Exemestane2006
• ExemestaneDrugs · 1999
• Exemestane-Associated Bilateral MaculopathyJAMA Ophthalmol · 2025
• Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent EvidenceAdv Ther · 2022
• Exemestane: a novel aromatase inactivator for breast cancerClin Breast Cancer · 2000
• Exemestane (FCE 24304), a new steroidal aromatase inhibitorJ Steroid Biochem Mol Biol · 1992
• Unravelling exemestane: From biology to clinical prospectsJ Steroid Biochem Mol Biol · 2016
• Exemestane: a review of its use in postmenopausal women with advanced breast cancerDrugs · 2000
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancerN Engl J Med · 2012
• Exemestane in advanced breast cancerAnticancer Drugs · 2000
• Exemestane in postmenopausal women with early or advanced breast cancer: a reviewExpert Opin Pharmacother · 2010